Source: Precision Medicine Online, June 2025
NEW YORK – Patients with symptomatic melanoma brain metastases harboring BRAF V600 mutations fared better on a combination of targeted therapy and immunotherapy as a first-line treatment compared to a dual checkpoint inhibitor combo.